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Background: The carotid artery is frequently patched after carotid endarterectomy (CEA) to minimize the risks of early
postoperative thrombosis and late recurrent stenosis. The small intestinal submucosa (SIS) patch is a biologic vascular
patch derived from porcine small intestine. It is composed primarily of cell-free collagen and other extracellular matrix
constituents that act as a scaffold for host cell deposition.
Methods: InMay 2001, we began an investigational trial of SIS patches in 76 patients undergoing patch angioplasty of the
carotid artery after CEA.
Results: No adverse events related to the patches were observed in the first 69 patients implanted with an SIS patch.
However, in late 2002, seven patients were found to have asymptomatic pseudoaneurysms (PSA) by duplex imaging<10
weeks after their CEAs. The trial was immediately suspended. The PSAs were treated by surgical resection with vein
grafting in two patients and placement of covered endoluminal stents in four patients. One patient is being followed as
the PSA is small and has remained stable. Histopathologic examination of the SIS patch explanted from one of the
surgically treated patients demonstrated the presence of actin-positive myofibroblasts or smooth muscle cells. Extensive
mechanical testing of the SIS material from the two material lots associated with PSAs demonstrated thinner and more
variable physical characteristics compared with control device lots.
Conclusions: Biologic patches that undergo active remodeling in the carotid artery require greater thickness than was
anticipated to decrease wall stress and suture hole elongation. Patches exceeding this minimum thickness will be required
to ensure the safety of new SIS patch designs for vascular operations. ( J Vasc Surg 2005;41:782-8.)Patch angioplasty of the carotid artery after endarterec-
tomy is frequently performed to minimize the risks of early
postoperative thrombosis and late recurrent stenosis.1-5
Standard materials used for patch angioplasty after carotid
endarterectomy (CEA) include autogenous tissues such as
saphenous or external jugular veins, bovine-derived tissue,
and prosthetic patches. Complications associated with
these patches include rupture and aneurysm formation for
saphenous vein patches, infection and excessive bleeding
for prosthetic patches, and aneurysmal dilatation of bovine
pericardial patches.6-11 The search for the Holy Grail in
vascular graft material continues. Desirable attributes of an
ideal graft material would include nonthrombogenicity,
resistance to infection or aneurysm formation, excellent
patency rates, and ready availability.
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782The small intestinal submucosa (SIS) product Surgisis
(Cook Biotech, Inc, West Lafayette, Ind) was developed as
a unique biologic vascular graft. It is produced from por-
cine small intestine by the mechanical removal of the mu-
cosa and the muscle layers, leaving the submucosa—a tissue
composed of acellular collagen and other extracellular ma-
trix components and proteins.12 The resultant material is a
cell-free translucent layer approximately 100 m thick,
which undergoes processing to eliminate cell-borne patho-
gens and viruses. Multiple layers are laminated to form a
biologic vascular patch designed to have sufficient strength
for clinical use.
The SIS material allows capillary ingrowth that results
in the patch being gradually replaced by the patient’s own
tissues. At 90 days after implantation in experimental ani-
mals, single-layer, nonsterile SIS grafts remodel to become
host tissue that is histologically identical to normal artery.13
These same grafts are extremely resistant to infection, and
are strong, nonthrombogenic, and remain patent over
time.14
Minimum strength and thickness requirements for SIS
and other uncrosslinked biologic vascular patch materials
that undergo rapid incorporation into and replacement by
the patient’s own tissues have not been previously reported.
Because the mechanical integrity of the remodeling tissue
undergoes a transient decrease before gradually maturing
and becoming stable, fabricating a biologic vascular patch
with this remodeling phenomenon in mind is critical to the
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configuration was developed with these design consider-
ations in mind, and was approved for human use by the
United States Food and Drug Administration (FDA).
Because we believed that the preclinical animal studies
demonstrated that single-layer, nonsterile SIS patches pos-
sessed many of the attributes of an ideal vascular patch, we
began a clinical confirmatory study with these sterile mul-
tilaminate SIS patches in a series of patients undergoing
CEA. We present our clinical results and show for the first
time clinically based minimum thickness requirements for
an uncrosslinked, biologic vascular patch material in the
carotid artery.
SIS PATCH FABRICATION
The SIS vascular patch material used in this study
consisted of four layers of SIS that were derived from the
trilaminate portion of the porcine small intestine, including
the stratum compactum of the tunica mucosa, the tunica
muscularis mucosa, and the tunica submucosa. The patch
material was minimally processed to lyse all resident cells
and remove cellular debris, was subjected to oxidative
treatment to eliminate the risk of disease transmission,26
and was terminally sterilized by a proprietary method that
included treatment with ethylene oxide gas.
The SIS vascular patches used in this study were pro-
vided by Cook Biotech Inc, West Lafayette, Ind, as part of
a clinical confirmatory study of the device after FDA regu-
latory approval.
Mechanical testing. Mechanical testing was per-
formed to examine the pre-implant thickness, tensile
strength, and suture retention strength of the material lots
from which the SIS vascular patches were produced.
Tensile test. Each sample was cut into a dog bone
configuration (65 mm long, 5 mm at the narrow portion).
Samples were rehydrated in water for 5 minutes, and the
thickness was measured in three places using calibrated
calipers. Samples were pulled to failure on an Instron
88800-DynaMight series tensile tester with a travel rate of
100 mm/min. Data from each test were logged using an
Instron Single Axis Max data acquisition system at a sample
rate of 100 Hz. Maximum load to failure was recorded.
Suture retention strength. Samples were cut into
10-mm  20-mm pieces and rehydrated in water for 5
minutes. Prolene sutures (5-0) (Ethicon) were secured to
each piece at a bite depth of 2 to 3 mm with at least 4 knots.
Samples were secured to clamps and tested on an Instron
8800-DynaMight series tensile tester with a travel rate of
100 mm/min. Data from each test were logged using an
Instron Single Axis Max data acquisition system at a sample
rate of 100 Hz. Suture pullout strength was recorded in
newtons and converted to grams force.
CLINICAL TRIAL
Beginning in May 2001, SIS vascular patches were
implanted in a series of 76 patients undergoing CEA at
Methodist Hospital (Clarian Health Partners, Inc, India-
napolis, Ind) (60 patients) and St. Vincent Hospital (Indi-anapolis, Ind) (16 patients) in an investigational review
board-approved trial. All patients gave informed consent.
Patients were excluded for any of the following reasons: a
history of previous radiation therapy to the cervical region,
long-term corticosteroid or immunosuppressive treatment,
vasculitis or collagen-vascular disease, or known allergy to
porcine-derived products.
All procedures were performed under general anesthe-
sia. All patients underwent a standard endarterectomy, after
which the entire length of the arteriotomy was patched with
an SIS vascular patch. Patients were heparinized with 5,000
to 8,000 units of heparin, which was reversed with prota-
mine. Most patients also received low-molecular-weight
dextran (Baxter, Deerfield, Ill) at 25 mL/h for 12 hours
postoperatively. Cervical drains were placed selectively. A
6-0 Prolene or a 6-0 polytetrafluoroethylene (PTFE) su-
ture (W.L. Gore, Flagstaff, Ariz) was used to sew the patch
in place.
All patients underwent postoperative duplex imaging at
4 to 6 weeks, 6 months, 12 months, and then yearly.
RESULTS
No postoperative deaths occurred among the 76 pa-
tients. Two patients had “watershed” infarcts postopera-
tively, as demonstrated by magnetic resonance imaging.
Both patients had critical bilateral carotid stenoses, and one
patient had had a recent stroke. Both patients underwent
postoperative carotid arteriography, which showed patent
internal carotid arteries with no intracranial abnormalities.
No abnormalities related to the SIS patches were noted.
Both strokes occurred after the first endarterectomy in each
patient. Shunts were used in both patients.
One patient was returned to the operating room for
evacuation of a cervical hematoma. The bleeding site was
from an arterial branch in the muscle. In one patient, a
superficial wound infection developed without involve-
ment of the patch.
Three patients required reoperation during late follow-
up. A symptomatic 60% to 70% recurrent stenosis devel-
oped at 23 months in one patient. In the other two pa-
tients, asymptomatic recurrent stenoses80% developed at
9 and 19 months postoperatively, secondary to intimal
hyperplasia. These three patients underwent repeat endar-
terectomies without complications, and no unusual techni-
cal difficulties were encountered. The SIS patches in these
three patients could not be distinguished from the normal
carotid artery.
An asymptomatic recurrent stenosis developed in a
fourth patient at the 15-month follow-up. This patient was
subsequently treated at another hospital with a carotid
artery stent. No further details were available.
Four patients were lost to long-term follow-up, al-
though three did return for a 6-week postoperative duplex
scan that demonstrated no recurrent stenoses or aneurys-
mal dilatation of the patch. No other patients had signifi-
cant recurrent stenoses on follow-up duplex scans, with up
to 3-year follow-up (mean, 20.8 months; range, 12 to 36
months).
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cause of death was a myocardial infarction in 3 patients,
renal failure in 1, and septic shock in 1 not related to the
CEA. The cause of death in the other two patients was
unknown. In none of these seven deaths was the cause of
death thought to be related to the patch.
No adverse events related to the patches occurred until
November 2002, when seven patients were found to have
asymptomatic pseudoaneurysms (PSAs) 10 weeks after
their endarterectomies. These patches had been implanted
Fig 1. A, Cerebral angiogram shows a pseudoaneurysm at the
endarterectomy site. B, Exclusion of the pseudoaneurysm after
placement of two Wallgrafts.over an 8-week period and were from two specific lots ofpatch material; six of the seven were from a single lot. The
trial was immediately suspended.
One of these seven patients is being observed, as the
PSA is quite small and no thrombus was seen within the
PSA by either duplex imaging or cerebral angiography.
The PSA has remained stable with 24-month follow-up.
The other six patients were treated either with resection
of the PSA with interposition vein grafting (2 patients)
or exclusion of the PSA with endoluminal covered stent
grafts (4 patients).
The first patient was treated with resection of the PSA
by the placement of an interposition saphenous vein graft.
This operation was technically very challenging because of
the intense inflammation surrounding the PSA. No suture
line could be identified, and it appeared that the SIS patch
had literally disintegrated. Aerobic and anaerobic cultures
of the PSA grew no organisms. At 6-month follow-up, a
stenosis was noted at the distal anastomosis of the interpo-
sition vein graft. The patient refused arteriography, and 2
weeks later was readmitted with a mild right hemispheric
stroke secondary to right middle cerebral artery infarct.
Magnetic resonance angiography showed that the vein
graft was occluded.
Because of the technical difficulties with the initial case,
the PSAs in the next four patients were excluded with
Wallgrafts (Boston Scientific, Natick, Mass) (Fig 1). In two
of these patients, symptomatic distal emboli developed into
branches of the middle cerebral arteries during deployment
of the stents, presumably secondary to embolization of
thrombus within the PSAs (Fig 2). The neurologic deficits
resolved spontaneously in one patient and after lytic ther-
apy in the other. Cerebral protection devices were not used
Fig 2. Cerebral angiogram shows thrombus (arrow), which was
lysed with thrombolytic therapy, in a branch of the middle cerebral
artery.in these four patients.
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the PSAs in all four patients. One patient treated with an
endoluminal stent had an asymptomatic occlusion of the
stent at 12 months, as demonstrated by duplex imaging.
The details of the interventions have been published.15
The final patient was treated with an interposition
saphenous vein graft. The angiogram demonstrated exten-
sive calcification of the common carotid artery, and place-
ment of a Wallgraft was determined not to be technically
feasible. This patient underwent surgical resection of the
PSA with placement of an interposition vein graft. Opera-
tive cultures of the PSA grew no organisms. The graft was
patent on duplex imaging at 20 months.
We were able to obtain biopsies of this patient’s
native carotid artery and the SIS patch material. His-
topathologic examination of the native artery demon-
strated an arterial wall composed of normal-appearing
Fig 3. A,Biopsy specimen (hematoxylin and eosin,100) from a
section of native artery that had undergone carotid endarterectomy
8 weeks before shows an arterial wall composed of normal-appear-
ing arterial muscle with no neointima, minimal inflammatory
changes, and discontinuous endothelium. B, Same specimen at
200. L, Lumen; p, remnants of vascular patch
.arterial muscle cells, with no neointima, minimal inflam-matory changes, and discontinuous endothelium (Fig 3).
Examination of the SIS patch material demonstrated a
layer of connective tissue circumferentially arranged
around the lumen consisting of actin-positive myofibro-
blasts or smooth muscle cells, and minor inflammatory
changes. Endothelium was absent (Fig 4).
The seven patches that developed PSAs came from two
specific lots of patch material. The remaining material from
these two lots was tested for its physical properties, includ-
ing thickness, suture retention strength, and tensile
strength. Maximum load to failure was recorded, and ten-
sile stress (strength/cross-sectional area) was subsequently
calculated to offer a more direct mechanical comparison
between samples.
The stress measurement takes the cross-sectional area
into account and is often used as a more accurate measure-
ment of the intrinsic mechanical properties of the material,
because slight differences in sample thickness can have a
profound effect on the tensile strength measurement.
Data obtained from these two lots and a comparison
population of 20 devices are presented in the Table. The
material from these two lots that was associated with PSAs
was thinner than the device population, and the second lot
demonstrated more variable tensile strength and suture
retention strength compared with control device lots
Fig 4. A biopsy specimen from a section of arterial wall that
had been replaced with the small intestinal submucosa (SIS)
vascular patch after carotid endarterectomy 8 weeks before
shows newly formed arterial tissue overlying the remnants of the
vascular patch. Luminal to the SIS layer, the replaced arterial
wall is composed of a new layer of connective tissue circumfer-
entially arranged around the lumen and consisting of spindle-
shaped fibroblasts and more mature fibrocytes (arrows) mini-
mally separated by collagenous ground substance. Scant
numbers of neutrophils are present in the most luminal portions
of the section, but inflammatory changes are generally minimal.
Immunohistochemistry confirmed the presence of actin-posi-
tive myofibroblasts or smooth muscle cells. Endothelium is
absent. (Actin 400.)(Fig 5).
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SIS grafts have been extensively studied in animals,
where they have been used to replace small and large
diameter arteries and veins, but circumferential tubes of SIS
have not been used in the human vascular system.16-20 The
experimental SIS vascular patch used in this study was the
first attempt to engineer an SIS device specifically tailored
to meet the demands of the human vascular system.
Although strength requirements are known for syn-
thetic patch materials, the requirements of a remodeling
biologic material have not been established. The series of
patients reported here represents the initial findings of a
patch designed to withstand the rigorous demands of the
vascular system after CEA and contributes to the establish-
ment of minimum mechanical properties required for bio-
logic graft materials that undergo active remodeling.
The SIS graft is a cell-free collagen-containing extra-
cellular matrix material that also contains glycoproteins,
proteoglycans, glycosaminoglycans, and growth factors
that signal the patient’s cells to replace the SIS scaffold with
native tissues.21-22 This process begins soon after implan-
tation, with the host tissues essentially replacing the SIS
graft over time. The SIS grafts have directional porosity,
with the mucosal side being the blood-contacting sur-
face.20 This side supports rapid cell attachment and endo-
thelialization. The more porous extraluminal surface allows
for prompt capillary ingrowth.12 At 28 days after implan-
tation in animals, single-layer, nonsterile SIS grafts are
completely endothelialized, and smooth muscle cells are
seen within the media.12 At 90 days, the single-layer SIS
grafts have remodeled to become host tissues and are
histologically identical to normal adjacent arteries.
The SIS grafts also have the ability to “regulate” the
wall thickness of the graft according to the stresses encoun-
tered in the arterial or venous circulation.18 When these
same single-layer SIS grafts are used to replace the superior
vena cavae of dogs, they become histologically indistin-
guishable from the normal adjacent vena cava.19
The compliance and burst strength of tubularized SIS
grafts have been studied experimentally.23 The compliance
values for the SIS grafts are only slightly less than those of
canine femoral arteries and are much higher than those for
Dacron (DuPont) and PTFE grafts, which should lead to
less intimal hyperplasia, a finding that has been observed in
experimental animal models.6-11 The burst strength for
Results of the mechanical testing investigation
Parameter
PSA
Lot 1
Thickness (mm) 0.292  0.018
SRS (transverse) (gF) 724.7  204.8
Strength (long) (N) 24.12  12.44
Stress (long) (Mpa) 15.72  8.31
P  0.05 – suture retention strength (SRS). The patches that developed a
*Significantly thinner than the control devices.small diameter SIS grafts far exceeds systolic blood pres-sure, attesting to its strength.23 SIS grafts have been ob-
served for up to 5 years in animals without evidence of
aneurysm formation.18
Testing has been performed to evaluate multilayer
forms of SIS used in the repair of full-thickness body wall
defects in dogs.24-25 Ball burst tests that measure the
strength of the SIS material at various times after implan-
tation demonstrate that at 10 days after implantation, the
SIS implant has about half of its original strength as it
undergoes remodeling.23 However, at 24 months, the SIS
material has twice its original strength and exceeds the
strength of native tissue.
Handmade tubular SIS grafts in animals have been used
to replace aortas, carotid and femoral arteries, and superior
vena cavae with excellent patency rates compared with
autogenous saphenous veins.13-14,16-18 The SIS grafts are
rich in heparin, which may provide local anticoagulation
while the fibrin formed on the luminal surface becomes
organized.16 In addition, investigators have noted a paucity
of platelet deposition on SIS grafts in animals compared
with PTFE and Dacron, which could also contribute to the
lack of thrombus formation and the excellent patency rates
seen experimentally in SIS grafts.16
SIS grafts are extremely resistant to infection, as no SIS
graft infections were noted in 300 vascular implants in
dogs.14 Badylak et al13 compared the resistance to infection
of PTFE and SIS grafts implanted into the infrarenal aortas
of dogs, which were then directly inoculated with Staphy-
lococcus aureus organisms. When the animals were sacri-
ficed, the PTFE grafts all showed evidence of infection,
including one animal that died of anastomotic hemorrhage.
None of the SIS grafts showed evidence of infection, and all
had negative cultures.
From a technical perspective, the SIS patches handle
well in terms of ease of suturing, with minimal needle-hole
bleeding. Only one patient in our series developed a hema-
toma and required reoperation. The bleeding source in this
patient was an arterial bleeder in the sternocleidomastoid
muscle.
We have used this same SIS patch in patients undergo-
ing femoral endarterectomies or profundaplasties without
the complications that were encountered in the carotid
artery.
PSAs developed in seven patients in our series. One
patient was not treated because the PSA was small, and it
PSA
Lot 2 Control
0.248  0.009* 0.325  0.046
796.9  72.5 843.4  156.1
17.81  3.59 17.90  4.2
13.61  2.41 10.51  2.74
aneurysm (PSA) were from Lot 1 (1 patient) and Lot 2 (6 patients).has remained stable in size on follow-up for 24 months.
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large enough that there was concern about possible com-
pression of adjacent structures in the neck.
Among the 69 other patients in our series in whom the
Surgisis patches were used, the results were excellent, with
mean follow-up of 20.8 months. We consider that the
incidence of recurrent stenosis was not excessive. Only a
larger series of patients could determine whether the SIS
patches have a higher incidence of recurrent stenosis com-
pared with prosthetic or autogenous patches. Parentheti-
cally we would add that in addition to the 76 patients in our
trial, SIS patches were used in another 25 patients outside
the trial. No pseudoaneurysms or significant recurrent ca-
rotid artery stenoses developed in any of these patients.
In the three patients who required reoperation for
recurrent stenosis, the patch material was not distinguish-
able from the native artery. This would lead to the conclu-
sion that, as in experimental animals, the SIS patch in
humans does indeed function as a scaffold, becoming re-
placed by the patient’s own tissues. The advantages of such
a transformation are obvious and suggest that SIS grafts
could be used in the treatment of aneurysmal and occlusive
disease. SIS grafts could have an important role in the
treatment of vascular infections.
The obvious question to be raised from this report is
what happened to the 7 patches that became aneurysmal?
The assessment of the physical characteristics of the lots
from which the patches were made showed that both
subject lots were similar to the device population with
respect to mean suture retention strength, tensile strength,
and tensile stress. However, the material lots which devel-
oped PSAs were either significantly thinner or had more
variable characteristics than the control device population.
There appears to be a clear correlation between these
attributes and PSA development, indicating that the phys-
iologic stress encountered by the patch exceeded the me-
chanical strength of the device. This information provides a
new, clinically relevant strength minimum for designing a
biologic vascular graft material—a device that remodels and
undergoes replacement with the patient’s own tissues and
gradually assumes its own physical characteristics.
CONCLUSIONS
The SIS biologic vascular patches possess several prop-
erties of an ideal vascular patch. Although this began as a
confirmatory study of biologic patch utility for CEA, we
also established for the first time clinically relevant mini-
mum thickness and strength requirements. It appears that
the minimum thickness for the SIS patch is 3 mm, which is
greater than what was anticipated from the experimental
data. Patches exceeding this minimum strength require-
ment will be required to ensure the safety of any new
biologic patch designs for vascular operations.
The assessment of the physical characteristics of the lots
from which the patches were made showed that both of the
subject lots were similar to the device population with
respect to the average suture retention strength, tensile
strength, tensile stress, and suture hole elongation. How-ever, the material lots were significantly thinner and had
more variable physical characteristics than the control de-
vice population. In those patients who developed PSAs, we
believe that the physiologic stresses encountered by the
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Fig 5. Testing of the material lots from which the patches were
made showed that Lot 2 was much thinner than the average
population of devices (A) and that Lot 1 was highly variable in the
properties of tensile strength (B) and suture retention strength (C)
compared with the controls.patch exceeded the mechanic integrity of the patch.
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